{"schema_version":"secwatch.filing_event.v1","accession":"0001854270-23-000032","form_type":"8-K","ticker":"SNTI","cik":"0001854270","company_name":"Senti Biosciences, Inc.","filed_at":"2023-03-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.172122+00:00","generated_at":"2026-06-17T21:41:43.760177+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Senti Bio reports FY2022 net loss of $58.2M; cash runway through Q1 2024; IND on track for H2 2023","bullets":["Cash, cash equivalents & short-term investments of $98.6M as of Dec 31, 2022; expect funding through at least Q1 2024.","FY2022 net loss $58.2M ($2.23 per share) vs $55.3M ($19.00 per share) in 2021; R&D expenses $34.1M, G&A $40.8M.","SENTI-202 IND application for AML/MDS planned in H2 2023; preclinical data to be presented at AACR April 2023.","Capital expenditures of $8.5M in Q4 2022 driven by cGMP manufacturing facility buildout and equipment.","Collaborations with Spark Therapeutics and BlueRock Therapeutics advancing Gene Circuit programs."],"urls":{"canonical":"https://secwatch.observer/filing/0001854270-23-000032","json":"https://secwatch.observer/filing/0001854270-23-000032.json","markdown":"https://secwatch.observer/filing/0001854270-23-000032.md","text":"https://secwatch.observer/filing/0001854270-23-000032.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1854270/000185427023000032/0001854270-23-000032-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1854270/000185427023000032/snti-20230322.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T21:41:43.760177+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"619d7ab5d606d708c2a2e17e925829a2ee576add","claim":"Senti Biosciences, Inc. reported the year ended December 31, 2022 results: net income Net loss ... $58.2 million, EPS $2.23 per share.","evidence_excerpt":"Senti Biosciences, Inc. issued a press release announcing its financial results for the year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1854270/000185427023000032/0001854270-23-000032-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Net income","value":"Net loss ... $58.2 million"},{"label":"EPS","value":"$2.23 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}